Tokyo, Japan

Teruo Akuta

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Teruo Akuta: Innovator in Pharmaceutical Compounds

Introduction: Teruo Akuta, an accomplished inventor based in Tokyo, Japan, has made significant contributions to the field of pharmaceutical innovation. His pioneering work culminated in a patent that focuses on a unique compound aimed at activating essential proteins in the body.

Latest Patents: One of Akuta’s notable patents is for the "Nitroguanosine-3',5'-cyclic monophosphate compound and protein kinase G activating agent." The primary objective of this invention is to provide a novel compound that acts as an agonist of guanosine-3',5'-cyclic monophosphate, which is crucial for activating protein kinase G. The patent presents the 8-guanosine-3',5'-cyclic monophosphate compound and positions it as a vital component in pharmaceutical compositions aimed at enhancing the activity of protein kinase G.

Career Highlights: Teruo Akuta works at Kumamoto University, where he applies his knowledge in pharmaceutical sciences to drive innovative research. His dedication to advancing medical science through invention has been instrumental in developing compounds that have therapeutic potential.

Collaborations: Throughout his career, Akuta has collaborated with notable researchers, including Takaaki Akaike. These collaborations have helped advance the understanding of protein kinases and their significance in various biological processes.

Conclusion: Teruo Akuta's contributions to the field of pharmaceutical compounds underscore the vital role of inventors in driving innovation. His patent on the Nitroguanosine-3',5'-cyclic monophosphate compound serves as a testament to the potential of scientific inquiry and collaboration in creating new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…